ERG induces taxane resistance in castration-resistant prostate cancer-Reference-Cited by-同舟云学术

ERG induces taxane resistance in castration-resistant prostate cancer

Published:2014-11-25 Issue:1 Volume:5 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Galletti Giuseppe,Matov Alexandre,Beltran Himisha,Fontugne Jacqueline,Miguel Mosquera Juan,Cheung Cynthia,MacDonald Theresa Y.,Sung Matthew,O’Toole Sandra,Kench James G.,Suk Chae Sung,Kimovski Dragi,Tagawa Scott T.,Nanus David M.,Rubin Mark A.,Horvath Lisa G.,Giannakakou Paraskevi,Rickman David S.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms6548.pdf

Reference71 articles.

1. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

2. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl. J. Med. 351, 1513–1520 (2004).

3. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 351, 1502–1512 (2004).

4. Mitchison, T. & Kirschner, M. Dynamic instability of microtubule growth. Nature 312, 237–242 (1984).

5. Waterman-Storer, C. M., Worthylake, R. A., Liu, B. P., Burridge, K. & Salmon, E. D. Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts. Nat. Cell Biol. 1, 45–50 (1999).

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer;Journal of Ethnopharmacology;2024-09

2. Computational Analysis of Treatment Resistant Cancer Cells;2024-08-31

3. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial;Nature Medicine;2024-08-20

4. The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials;European Urology Oncology;2024-07

5. The Role of Tumor‐Derived Extracellular Vesicles in Drug Resistance in Urologic Cancers;Advanced Therapeutics;2024-05-25